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ABSTRACT 
Severe sepsis is associated with high mortality and is a common problem in the United States. 
Recently, studies have shown that efforts focused on lowering cytokine levels improve survival. 
The aim of this work is to define sepsis endotypes using longitudinal cytokine measurements.    
Sepsis endotypes were defined using latent class mixture models. Latent class mixture 
models were modeled using a natural log transformation of the actual time measurements. The 
outcome was the natural log of the cytokine value. No other covariates were modeled and a 
parameterized link function using a basis of I-splines was chosen over a linear transformation to 
increase flexibility in the latent class trajectories. The number of latent classes were determined 
by a combination of the lowest BIC and clinical significance.  
After creating models for a variety of subsets derived from the source population, it was 
determined that mortality within a particular trajectory class is not only dependent upon the 
baseline cytokine value, but also dependent upon the rate of decent after baseline. A class with 
high baseline cytokine values that decrease quickly has lower mortality rates than classes who do 
not decline quickly. It was also determined that those who have increasing cytokine values from 
baseline to 6 hours have worse outcomes than those who decrease in the same time frame.  
v 
Public Health Significance: Given the public health significance of sepsis, understanding 
prognosis is extremely important. Previously, having a high IL6 measurement implied a poor 
prognosis. Our results show that many factors play into the determination of prognosis and patients 
can be treated accordingly. 
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1.0  INTRODUCTION 
Severe sepsis is a common problem that is associated with a high mortality rate. In 1990, it was 
estimated that there were 450,000 cases of sepsis per year in the United States (Angus et al., 2001). 
In 2003, Hotchkiss et al. discussed circulating TNF levels and the relationship of high levels with 
mortality. The merits of lowering cytokine levels in septic patients has been shown in a recent 
study in which a subgroup of septic patients had improved survival when therapy was directed 
against TNF (Hotchkiss & Karl, 2003). An analysis of anti-inflammatory agents in septic patients 
also showed that a small subgroup, approximately 10%, benefited from high doses of these anti-
inflammatory agents. (Hotchkiss & Karl, 2003). Many studies focusing on lowering cytokines 
levels at this time do not use longitudinal data but recently, the idea of latent canonical trajectory 
classes has been proposed. Defining trajectory classes allows septic patients to be placed into a 
specific endotype allowing for a more accurate understanding of prognosis. Endotyping involves 
placing patients into a subtype of the condition being studied and could be defined by a 
pathobiological mechanism or a treatment response. Endotyping helps to better assess risk and 
mortality.  
 The idea of endotyping with longitudinal cytokine measurements has been discussed by 
Kellum et al. in 2008. They describe the systemic cytokine response to pneumonia and determine 
if specific patterns are associated with severe sepsis and death (Kellum, 2008). It was determined 
that unbalanced, or high/low, cytokine patterns were unusual (4.6%) and not associated with 
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decreased survival. The highest risk of death occurred with combined high levels of the pro-
inflammatory IL-6 and anti-inflammatory IL-10 cytokines (Kellum, 2008). This analysis used 
longitudinal daily cytokine measurements over the first week and modeled the cytokine trajectories 
as cubic polynomials over time. This analysis can be improved upon by using the Protocol-Based 
Care for Early Septic Shock (ProCESS) data. The ProCESS data was collected from a randomized 
trial at 31 hospitals in the United States.  
 The ProCESS data measures cytokines IL6 and Il10 at baseline (0 hours), 6 hours, 24 hours 
and 72 hours. This allows trajectories to have a better representation of the critical first day post 
enrollment. The ProCESS data set is more complete with data on patients that have increasing 
trajectories and is not limited to the systemic cytokine response to pneumonia. The main aim of 
this paper is to define endotypes within septic patients for a more accurate understanding of 
prognosis. To address this aim, latent classes were defined using latent class mixture models. 
Specifically, we looked for trajectory classes in all patients as well as those whose cytokine levels 
increased from baseline to 6 hours and in those whose cytokine levels decreased from baseline to 
6 hours.  
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2.0  METHODS 
2.1 STUDY POPULATION 
The ProCESS study enrolled subjects at 31 hospitals in the United States. Subjects were recruited 
from the emergency department if sepsis was suspected according to the treating physician, they 
were at least 18 years of age, met two or more criteria for systemic inflammatory response 
syndrome and who had refractory hypotension or a serum lactate level of 4 mmol per liter or 
higher. Patients were excluded if a primary diagnosis of acute cerebral vascular event, acute 
coronary syndrome, acute pulmonary edema, status asthmaticus, major cardiac arrhythmia, 
active gastrointestinal hemorrhage, seizure, drug overdose, burn or trauma; a requirement for 
immediate surgery; a known CD4 count <50/mm2; an advance directive that would restrict 
protocol implementation; a contraindication to central venous catheterization; a high likelihood of 
refusing blood transfusion; a treating physician who deemed resuscitation to be futile; on-going 
participation in another interventional study; known pregnancy, or; been transferred from another 
hospital (Process Investigators, 2014). Patients were randomized to one of three treatment groups: 
protocol-based early goal directed therapy (EGDT), protocol-based standard therapy, or usual care 
in a 1:1:1 ratio. Based on the results of the original study, the three interventions were combined 
into one intervention group (Process Investigators, 2014).  
Two cohorts of patients were used for the analysis. The complete measurement cohort was 
composed of patients who had IL6 and IL10 measurement at 0 hours, 6 hours and 24 hours at the 
minimum. Note that individuals with only the first three out of four time points were considered 
in the complete measurement set even though they are not a true complete measurement set. 
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Including these individuals allowed for a larger subset of the data. This subgroup may present a 
survivor bias, so an additional cohort was considered called the whole cohort. This group consisted 
of patients with at least one IL6 and at least one IL10 measurement.  
The whole cohort and the complete measurement cohort were further divided into 2 groups: 
those who had an increasing cytokine measurement from hour 0 to hour 6 and those with a 
decreasing cytokine measurement from hour 0 to hour 6. These were referred to as the increasing/ 
decreasing subsets. Individuals whose cytokine measures remain constant from hour 0 to 6 are not 
included in these analyses. 
All patients or their legal representatives provided an informed written consent. The 
institutional review board at the University of Pittsburgh and at all other participating site approved 
the study protocol.  
2.2 MEASUREMENTS 
The primary outcomes of the study were values for the cytokines IL6 and IL10. These cytokines 
were measured at 0 hours, represented by the entrance to the study, 6 hours, 24 hours and 72 hours. 
Mortality at 60 days for any reason was also measured. Demographic variables included sex, age 
and race (black, white or other). Baseline measurements reflecting status of health include Acute 
Physiology and Chronic Health Evaluation (APACHE) II score, Sequential Organ Failure 
Assessment (SOFA) score, number septic by definition, systolic blood pressure (SPB), diastolic 
blood pressure (DBP), heart rate, temperature, respiratory rate, lactate, white blood cell count and 
binary variables use of mechanical ventilation, pre-randomization use of vasopressor and 
 5 
randomization to 6 hour vasopressor use. Time was measured as either the actual time (0, 6, 24 
and 72 hours) or ln (hours+1) to determine the best fit for the data.  
2.3 STATISTICAL METHODS LITERATURE REVIEW 
In order to better understand the latent class mixture model, a brief description follows. A standard 
linear mixed model assumes that everyone in the population is homogeneous and assumes that 
everyone in the population is described by a unique trajectory. In contrast, latent class mixture 
models assume that the population is heterogeneous and comprised of G mean profiles of 
trajectories, or classes, where an individual can belong to only one latent class. Using this model, 
it is important to define a structural model for the latent process, a measurement model that links 
the latent process to the scale of the observation and define probability (Proust-Lima, Philipps, & 
Liquet, n.d.). Latent variables are variables that cannot be directly observed. Rather, they are 
inferred from other observed variables. The structural model models the latent, or unobserved, 
process and the measurement model converts the unobserved latent value into our outcome of 
interest, natural log of the cytokine value.  
 In the structural model, the latent process is defined in continuous time according to the 
standard linear mixed model below. In the structural model, fixed and random covariates can take 
on any polynomial shape. Also note that the model does not include measurement errors (Proust-
Lima et al., n.d.).  
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Λ𝑖𝑖(𝑡𝑡)|𝑐𝑐𝑖𝑖=𝑔𝑔 = 𝑋𝑋1𝑖𝑖(𝑡𝑡)𝑇𝑇β + 𝑋𝑋2𝑖𝑖(𝑡𝑡)𝑇𝑇ν𝑔𝑔 + Z𝑖𝑖(t)𝑇𝑇𝛼𝛼𝑖𝑖𝑔𝑔,     ∀𝑡𝑡 ∈  ℝ 
where 
Λ𝑖𝑖(𝑡𝑡) is the latent process of patient i where i  = 1, 2, …, m 
m is the number of patients 
𝑐𝑐𝑖𝑖 is a latent random variable that equals g if patient i belongs to latent class g where g =1, 2, … G  
G is the total number of classes 
𝑋𝑋1𝑖𝑖(𝑡𝑡) is a vectors of covariates for patient i associated with fixed effects that are common over latent 
classes 
𝛽𝛽 is a vector of fixed effects that are common over latent classes 
𝑋𝑋2𝑖𝑖(𝑡𝑡) is a vector of covariates for patient i associated with fixed effects that differ by latent class 
ν𝑔𝑔 is a vector of fixed effects that differ depending on which latent class, g, a patient belongs 
Z𝑖𝑖(t) is a vector of covariates for patient i associated with individual random effects 
𝛼𝛼𝑖𝑖𝑔𝑔 is a vector of individual random effects  𝛼𝛼𝑖𝑖|𝑐𝑐𝑖𝑖=𝑔𝑔 whose distributions are class specific 
 𝛼𝛼𝑖𝑖𝑔𝑔~𝑁𝑁(0,𝜔𝜔𝑔𝑔2𝐵𝐵) where B is an unspecified variance covariance matrix and 𝜔𝜔𝑔𝑔 is a proportional 
 coefficient that allows for class-speciﬁc variance-covariance matrices of the random-effects 
 (In this paper, 𝜔𝜔𝑔𝑔= 1 for all classes implying the variance-covariance matrix is common over 
 latent classes) 
t is time   
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 The measurement model is defined between the latent processes Λ𝑖𝑖(𝑡𝑡) and the observed 
value  Y𝑖𝑖𝑖𝑖 for individual i at time j shown below (Proust-Lima et al., n.d.). The measurement model 
that will be used incorporates the use of splines instead of using a linear model or modeling with 
polynomial functions.  
 
𝑌𝑌𝑖𝑖𝑖𝑖 = 𝐻𝐻(Λ𝑖𝑖�𝑡𝑡𝑖𝑖𝑖𝑖� + 𝜀𝜀𝑖𝑖𝑖𝑖;  𝜂𝜂) 
 
𝑌𝑌𝑖𝑖𝑖𝑖 is the observed value for patient i at time j where i = 1, 2, …, m 
m is the number of patients 
H is a parameterized link function with parameters 𝜂𝜂 and is defined by a basis of quadratic I-splines 
Λ𝑖𝑖�𝑡𝑡𝑖𝑖𝑖𝑖� is the latent process of patient i at time j 
𝜀𝜀𝑖𝑖𝑖𝑖 are the independent normal measurement errors with mean 0 and variance 𝜎𝜎𝜀𝜀2 
 
 The parameterized link function is a basis of quadratic I-splines defined below. Splines 
extend the advantages of polynomials by allowing greater flexibility and are basically piecewise 
polynomials with specified continuity constraints.  Continuity and number of parameters depend 
on a knot sequence. If the spline were to be defined on an interval [L, U], the knots divide the 
interval into a number of subintervals. A given knot sequence is associated with a suitable set of 
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basis splines that can be combined linearly to produce any other spline associated with this knot 
sequence. This set of basis functions is then modified to provide a useful basis for monotone 
splines, also known as I-splines. The I-spline is referred to as quadratic when the piecewise 
polynomials are quadratic in shape. A 4 knot spline will be used in all models to remain consistent 
(Ramsay, 1988). 
𝐻𝐻−1�𝑌𝑌𝑖𝑖𝑖𝑖;  𝜂𝜂� =  𝜂𝜂0 + �𝜂𝜂𝑙𝑙25
𝑙𝑙=1
𝛽𝛽𝑙𝑙
𝐼𝐼�𝑌𝑌𝑖𝑖𝑖𝑖� 
𝐻𝐻−1 is the inverse of the parametrized link function  
𝑌𝑌𝑖𝑖𝑖𝑖 is the observed value for individual i at time j where i = 1, 2, …, m 
m is the number of patients 
𝜂𝜂𝑖𝑖 are the parameters of the link function, i = 0, 1, 2, 3, 4, 5 
(𝛽𝛽1𝐼𝐼 ,𝛽𝛽2𝐼𝐼 ,𝛽𝛽3𝐼𝐼 ,𝛽𝛽4𝐼𝐼 ,𝛽𝛽5𝐼𝐼) is the basis of I-splines 
 In the above parameterized link function, note that 𝐻𝐻−1 is a monotonic increasing 
continuous function. The parameters in the summation are squared in order to constrain the 
parameters to be positive.  
The probability of belonging to any one specific latent class is defined using a multinomial 
logistic regression and is shown below. When no covariates predict latent class membership, the 
model reduces to a class specific probability (Proust-Lima et al., n.d.). 
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𝜋𝜋𝑖𝑖𝑔𝑔 = 𝑃𝑃(𝑐𝑐𝑖𝑖 = 𝑔𝑔|𝑋𝑋𝑐𝑐𝑖𝑖) = 𝑒𝑒𝜁𝜁𝑜𝑜𝑜𝑜+𝑋𝑋𝑐𝑐𝑖𝑖𝑇𝑇𝜁𝜁1𝑜𝑜
∑ 𝑒𝑒𝜁𝜁𝑜𝑜𝑜𝑜+𝑋𝑋𝑐𝑐𝑖𝑖
𝑇𝑇𝜁𝜁1𝑜𝑜𝐺𝐺
𝑙𝑙=1
, 
where 
𝜋𝜋𝑖𝑖𝑔𝑔 is the probability that patient i belongs to class g where i = 1, 2, …, m and g = 1, 2, …, G 
m is the number of patients 
G is the number of classes 
𝑐𝑐𝑖𝑖 is a latent random variable that equals g if subject i belongs to latent class g  
𝑋𝑋𝑐𝑐𝑖𝑖 are covariates in the multinomial logistic regression 
𝜁𝜁𝑜𝑜𝑔𝑔 is the intercept to class g   
𝜁𝜁1𝑔𝑔 are the class-specific parameters associated with the covariates 𝑋𝑋𝑐𝑐𝑖𝑖 
 Bayesian Information Criterion (BIC) is a method that is commonly used to determine 
the number of latent classes in latent class mixture models. The model with the lowest BIC has 
the optimal number of classes. The formula for BIC is shown below. 
𝐵𝐵𝐵𝐵𝐵𝐵 = −2𝐿𝐿(𝜃𝜃𝐺𝐺) + 𝑝𝑝𝐺𝐺ln (𝑁𝑁) 
where 
G is the number of latent classes 
𝐿𝐿(𝜃𝜃𝐺𝐺) is the log-likelihood of the model 
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𝑝𝑝𝐺𝐺  is the number of estimated parameters 
N is the number of subjects 
 The BIC is preferred to the more well-known Akaike Information Criteria (AIC) as is favors 
more parsimonious models than AIC by penalizing for model complexity with ln(N) as compared to 2 in 
the AIC formula (Commenges & Jacqmin-Gadda, 2016).  
2.4 STATISTICAL ANALYSIS 
Statistical analyses will be performed using SAS version 9.4 and the R version 3.2.3 package 
LCMM. Statistical significance will be set at 0.05. All cytokine measurements will be analyzed in 
the natural logarithmic scale. If a cytokine has a value of 0 before the natural log transformation, 
its value will be changed to 1 in order to avoid undefined values post natural log transformation.  
 In order to make statistical comparisons between the whole and complete measurement sub 
groups, baseline analysis will be considered in the whole cohort, the complete measurement cohort 
and on the group of individuals who are in the whole cohort but not the complete measurement 
cohort, called the incomplete measurement cohort. This group is titled incomplete measurement 
cohort due to their lack of a complete measurement set. 
 Kaplan-Meier curves will be created for each of the two groups as well as in the incomplete 
measurement group to investigate any differences in mortality. Day of death will be used as the 
event time and time will be capped at 60 days as the administrative censoring day. Individuals will 
be censored at time of discharge if they were discharged from the hospital and a follow up was not 
completed. 
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 In order to create trajectories for IL6 and IL10, latent class mixture models will be created 
using the R program LCMM. Latent class mixture models are preferred over other types of 
trajectory analyses (e.g., latent group-based trajectory models) because random deviations from 
the mean trajectory are allowed for people belonging to the same latent trajectory group.  
 In the structural model piece of the latent class mixture models, candidates for fixed 
covariates over classes will include time squared, race, sex and age. The class specific fixed 
covariates and the random covariates will include time squared only. Time is modeled as time 
squared for these covariates due to previous work that showed that the data is not linear in regard 
to time and quadratic shapes better reflect the data. Time in these models will also be investigated 
as either actual time or ln (hours+1). It is suspected that using ln (hours+1) allows for better 
modeling of the polynomial shapes of time as it is more evenly spaced than the original time 
measurement. The variance-covariance matrix for the random effects will be diagonal. This 
indicates that the variance is equal between two time points that are the same but the covariance 
between two differing time points is 0. The parameterized link function will use a basis of quadratic 
I-splines with 4 knots.  
 The number of latent classes will be determined by finding the lowest BIC. In order to 
maintain clinical significance, the number of groups may be decreased to avoid classes with a 
small percent of the total population. Groups will be preferred to have at least 8 percent of the total 
population so that classes are large enough to have clinical significance. Confidence bands will be 
placed on each class in the trajectory models. Predictions in the outcome scale, ln (IL6) or ln 
(IL10), will be computed using a Monte Carlo approach with 2,000 draws. Latent class mixture 
models will be created in each of the two cohorts as well as in the increasing/ decreasing subsets. 
In the overall analyses, time will be modeled as actual and ln (hours+1). In, the increasing/ 
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decreasing analyses, time will only be modeled as ln (hours+1).  When modeling ln (hours+1), a 
grid search function will be used to find the best set of initial conditions. Grid search is derived 
from the Expectation Maximization (EM) technique and uses the parameters obtained from the 
best log-likelihood of a one class model after m iterations, in this case 20, and uses them as the 
initial values for the estimation of parameters in the final, g class, model (Proust-Lima et al., n.d.).  
 In each of the trajectory models, 60 day all-cause mortality will be calculated in each of 
the classes as the number of individuals who died at or before 60 days from any cause out of the 
number of individuals with a confirmed death status at 60 days. After discussion with a clinician, 
it was determined that the mortality rates are similar for those with a confirmed and those without 
a confirmed death status at 60 days. Therefore there is no bias in removing these individuals from 
the calculation. Mortality rates will also be compared between increasing and decreasing groups 
of IL6 and IL10 using a chi square test of proportions. It is suspected that those that increase 
initially will be caught earlier in the disease process and will have better mortality rates given that 
treatment began earlier.  
In order to investigate mortality patterns in the classes of IL6 and IL10, 60 day all-cause 
mortality will be calculated in all combinations of IL6 and IL10 classes formed from the overall 
analysis of the whole cohort. These classes will be ranked from low to high based on the baseline 
cytokine value in the trajectory and the information will be presented in a table. In order to analyze 
this table, pairwise chi-square tests of proportions with Bonferroni corrections for multiple 
comparisons will be computed on the mortality rates between classes in a particular column or row 
of the table.  
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3.0  RESULTS 
3.1 PATIENTS 
The ProCESS trial enrolled 1,351 individuals. Ten of the 1,351 patients asked to be removed from 
the study leaving a total of 1,341 patients for analysis. Of these 1,341 patients, 638 had at least 1 
time point measured, 617 had at least 2 time points measured, 563 had at least 3 time points 
measured and 167 had all four time points measured as seen in the consort table in Figure 1. 
 After defining subgroups, the whole cohort group had 638 patients with at least one IL6 
and IL10 measurement. Of these 638, 319 are decreasing IL10 and 159 are increasing IL10. Of 
the 638, 381 have decreasing IL6 and 202 have increasing IL6. The complete measurement cohort 
group has 549 patients with the first three time points or all four time points, 278 of which are 
decreasing IL10 and 126 have increasing IL10. Of the 549, 335 are decreasing IL6 and 169 are 
increasing IL6.  
 Table 1. shows the baseline and demographic values compared in each of the two main 
analysis cohorts as well as the group defined as the incomplete measurement cohort. All baseline 
characteristics are similar statistically between whole cohort and the complete measurement cohort 
with the exception of baseline and 6 hour ln (IL6) and ln (IL10) values, baseline lactate and 60 day 
all-cause mortality. Cytokine measurements are higher in the whole cohort as compared to the 
complete measurement cohort. Baseline lactate values are also higher in the whole cohort. When 
considering mortality, 60 day all-cause mortality is higher in the whole cohort as well.  
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Figure 1. Consort Table 
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Table 1. Baseline Characteristics between Groups1 2 
 WHOLE 
COHORT 
(N=638) 
COMPLETE 
MEASUREMENT 
COHORT 
(N=549) 
INCOMPLETE 
MEASUREMENT 
COHORT3 
(N=88) 
P-
VALUE4 
BASELINE LN (IL6)5 6.13±2.60 6.05±2.53 6.77±2.99 0.0254 
BASELINE LN (IL10)6 3.63±1.95 3.55±1.89 4.20±2.30 0.0078 
6 HOUR LN (IL6)7 5.68±2.44 5.61±2.30 6.43±3.37 0.0118 
6 HOUR LN (IL10)8 3.27±1.75 3.22±1.68 3.75±2.28 0.0249 
MALE  371(58.15) 326(59.38) 44(50.00) 0.0978 
AGE9 – YEARS 59.8±15.4 60±15.6 59.2±14.0 0.6821 
RACE    0.9422 
      BLACK  146(22.9) 127(23.1) 19(21.6)  
      WHITE  440(69.0) 377(68.7) 62(70.5)  
      OTHER  52(8.15) 45(8.20) 7(7.95)  
60 DAY MORTALITY10  165/573 (28.8) 125/492 (25.4) 40/81 (49.4) <0.0001 
BASELINE APACHE II SCORE 20.8±7.74 20.6±7.56 22.0±8.75 0.1114 
MECHANICAL VENTILATION11  243(38.2) 202(36.8) 41(47.1) 0.0654 
PRERANDOMIZATION VASOPRESSOR  116(18.2) 100(18.2) 16(18.2) 0.9940 
RANDOMIZATION TO 6 HOUR VASOPRESSOR  336(52.7) 289(52.6) 47(53.4) 0.8934 
BASELINE SOFA SCORE 7.14±3.62 7.06±3.58 7.64±3.86 0.1687 
SEPTIC BY DEFINITION12  623(97.7) 534(97.3) 88 (100.0) 0.1166 
BASELINE SBP 101±29.6 101±29.4 102±29.2 0.8409 
BASELINE DBP 59.1±20.0 59.2±19.7 58.2±19.8 0.6446 
BASELINE HEART RATE 112±24.4 111±24.5 116±22.3 0.1335 
BASELINE TEMPERATURE (𝑪𝑪𝒐𝒐)13 37.3±1.59 37.3±1.61 37.4±1.53 0.6362 
BASELINE RESPIRATORY RATE14 22.6±7.30 22.4±7.06 23.7±8.56 0.1114 
BASELINE LACTATE15 4.66±3.18 4.53±3.13 5.44±3.38 0.0135 
BASELINE WBC16 15.8±11.2 15.6±10.4 16.5±14.8 0.6105 
 
                                                 
1 Plus/minus values are mean ± standard deviation 
2 Unless otherwise notes, categorical variables are presented as Number (%) 
3 The incomplete measurement cohort plus the complete measurement cohort does not equal the total in the whole cohort. This is a 
 consequence of 1 patient with Il6 values that qualify them as a complete cohort and only one Il10 time point measured.  
4 P-values are calculated using t-tests for numeric variables and chi-squared tests for categorical variables between the complete cohort 
 and incomplete cohorts. 
5 Information on baseline ln (Il6) was missing for 16 patients in the whole cohort group and 16 patients in the incomplete measurement 
 cohorts. 
6 Information of baseline ln (Il10) was missing for 17 patients in the whole cohort group and 16 patients in the incomplete measurement 
 cohort. 
7 Information on 6 hour ln (IL6) was missing for 27 patients in the whole cohort group and 27 patients in the incomplete measurement 
 cohort. 
8 Information on 6 hour ln (IL10) was missing for 27 patients in the whole cohort group and 27 patients in the incomplete measurement 
 cohort. 
9 Information on age is missing for 11 patients in the whole cohort, 8 in the complete measurement cohort and 3 in the incomplete 
 measurement cohort.  
10 Number/Total (%) - Information on mortality at 60 days is not confirmed for 109 patients in the whole cohort group, 57 in the 
 complete measurement cohort and 1 in the incomplete measurement cohort. These individuals were removed from the analysis.  
11 Information on mechanical ventilation was missing for 1 patients in the whole cohort group and 1 patient in the incomplete 
 measurement cohort. 
12 Sepsis is defined as an acute change in SOFA score of 2 or more points. 
13 Information on Baseline Temperature was missing for 8 patients in the whole cohort group, 5 patients in the complete measurement 
 cohort and 3 patients in the incomplete measurement cohort.  
14 Information on Baseline Respiratory Rate was missing for 1 patients in the whole cohort group and 1 patients in the complete 
 measurement cohort  group.  
15 Information on Baseline Lactate was missing for 18 patients in the whole cohort group, 15 patients in the complete measurement 
 cohort and 3 patients in the incomplete measurement cohort. 
16 Information on Baseline WBC was missing for 336 patients in the whole cohort group, 293 patients in the complete measurement 
 cohort and 42 patients in the incomplete measurement cohort. 
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3.2 SURVIVAL 
The figure below shows the product limit survival estimates of the whole, complete measurement 
and incomplete measurement cohorts. The log rank test statistic comparing the complete 
measurement and incomplete measurement cohorts has a chi-squared test statistic of 31.64 with a 
p-value of <0.0001 indicating that the two survival curves are statistically different. 
 
 
Figure 2. Survival Estimates between Whole, Complete Measurement and Incomplete Measurement 
Cohorts 
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3.3 LATENT CLASS DETERMINATION 
After running all of the overall models, it was apparent that most of the models would have 3, 4 or 
5 classes with 4 classes being dominant. In order to preserve consistency between models and 
allow for easier clinical interpretation, all models were modeled with 4 classes. The only exception 
is the model for IL10 in the complete measurement cohort using ln (hours+1) times. For these data, 
the 4 class model included a fourth class which contained no patients. Therefore, a 3 class model 
was used.  
 After running the overall analysis in the whole and complete measurement cohorts using 
both actual and ln (hours+1) time, a spaghetti plot of the outcome was plotted against time. 
Comparing the trajectory classes and the spaghetti plots revealed that modeling time as ln 
(hours+1) better reflected the data. Models were also considered using rank times (1, 2, 3, 4) but 
were abandoned given the difficulty of clinical interpretation when data is measured at times other 
than 0, 6, 24 and 72 hours. When modeling with actual times, some classes took a parabolic shape 
that was not supported by the data. Only models using ln (hours+1) time will be discussed.  
For the increasing and decreasing analysis, models were determined using a combination 
of BIC, class size, as well as clinical significance. Considering BIC and removing a class size of 
less than 8% produced 2 class models in all IL6 and IL10, increasing and decreasing models. 
Adding clinical interpretation allowed a third class in the decreasing analysis of IL6 in all 
subgroups. All models use time as ln (hours+1) for the reasons stated above.  
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Sex, age, and race were only significant in a few of the models, so all covariates were 
removed to preserve consistency. In the figures for models one through twelve below, the 95% 
confidence intervals are shown around all class trajectories and each y-axis is shown on the actual 
cytokine scale, as opposed to the natural log of the cytokine measurement, in order to be more 
recognizable to clinicians. When modeling ln (hours+1), the x-axis has the actual hour 
measurement at the location of the ln (hours+1) time point.  
3.4 OVERALL ANALYSIS IN WHOLE COHORT 
The overall analysis of IL6 using ln (hours+1) time in the whole cohort is considered Model 1. 
Parameter estimates for Model 1 can be found in the table below. Class 1 is represented by a lower 
initial cytokine value with slow decline. Class 2 is represented by the highest initial cytokine value 
and later decline. Class 3 is represented by low and steady cytokine values. Class 4 is represented 
by higher initial cytokine values with quicker decline. In this model, 44.2% of the patients belong 
to Class 1, 1.88% of the patients belong to Class 2, 48.9% of the patients belong to Class 3 and 
5.02% of the patients belong to Class 4. A majority of the patients belong to Class 3. Mortality is 
as follows: Class 1 28.35%, Class 2 81.82%, Class 3 27.30% and Class 4 26.92%. A figure of the 
trajectory classes is shown below. 
 
 
 
 
 19 
 The overall analysis of IL10 using ln (hours+1) times in the whole cohort is considered 
Model 2. Parameter estimates for Model 2 can be found in the table below. Class 1 is represented 
by a higher initial cytokine value with slow decline. Class 2 is represented by a moderate initial 
cytokine value and slow decline. Class 3 is represented by low and steady cytokine values. Class 
4 is represented by the highest initial cytokine value with quicker decline. In this model 9.09% of 
the patients belong to Class 1, 20.06% of the patients belong to Class 2, 65.52% of the patients 
belong to Class 3 and 5.33% of the patients belong to Class 4. A majority of the patients belong to 
Class 3. Mortality is as follows: Class 1 48.15%, Class 2 21.93%, Class 3 27.01% and Class 4 
41.94%. A figuring comparing of the trajectory classes is shown below. 
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Figure 3. Overall Analysis of IL6 in Whole Cohort Using Ln (hours+1) Times – Model 1 
 
 
 
Figure 4. Overall Analysis of IL10 in Whole Cohort Using Ln (hours+1) Times – Models 2 
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Table 2. Parameter Estimates for Model 1 
 COEFFICIENT STANDARD 
ERROR 
WALD TEST 
STATISTIC 
P-
VALUE 
CLASS 1 INTERCEPT (NOT ESTIMATED) 0 - - - 
CLASS 2 INTERCEPT 7.26413 0.88566 8.202 <0.0001 
CLASS 3 INTERCEPT -3.1761 0.23772 -13.361 <0.0001 
CLASS 4 INTERCEPT 3.40528 0.71302 4.776 <0.0001 
TIME CLASS 1 0.36122 0.09507 3.799 0.00015 
TIME CLASS 2 1.21214 0.56797 2.134 0.03283 
TIME CLASS 3 -0.03986 0.08344 -0.478 0.63285 
TIME CLASS 4 -0.2318 0.31486 -0.736 0.4616 
TIME SQUARED CLASS 1 -0.32002 0.02873 -11.138 <0.0001 
TIME SQUARED CLASS 2 -0.7912 0.1827 -4.33 0.00001 
TIME SQUARED CLASS 3 -0.03413 0.0233 -1.465 0.14297 
TIME SQUARED CLASS 4 -0.46557 0.073 -6.378 <0.0001 
 
 
 
 
Table 3. Parameter Estimates for Model 2 
 COEFFICIENT STANDARD 
ERROR 
WALD TEST 
STATISTIC 
P-
VALUE 
CLASS 1 INTERCEPT (NOT ESTIMATED) 0 - - - 
CLASS 2 INTERCEPT -1.37894 0.41123 -3.353 0.0008 
CLASS 3 INTERCEPT -4.91086 0.35577 -13.804 <0.0001 
CLASS 4 INTERCEPT 1.8515 0.53788 3.442 0.00058 
TIME CLASS 1 0.73912 0.19786 3.736 0.00019 
TIME CLASS 2 -0.71192 0.16576 -4.295 0.00002 
TIME CLASS 3 0.14351 0.06728 2.133 0.03291 
TIME CLASS 4 0.99133 0.27537 3.6 0.00032 
TIME SQUARED CLASS 1 -0.36791 0.05345 -6.884 <0.0001 
TIME SQUARED CLASS 2 -0.14199 0.03885 -3.655 0.00026 
TIME SQUARED CLASS 3 -0.09596 0.01761 -5.448 <0.0001 
TIME SQUARED CLASS 4 -0.8283 0.08176 -10.131 <0.0001 
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3.5 OVERALL ANALYSIS IN COMPLETE MEASUREMENT COHORT 
The overall analysis of IL6 using ln (hours+1) times in the complete measurement cohort is 
considered Model 3. Parameter estimates for Model 3 can be found in the table below. Class 1 is 
represented by a lower initial cytokine value that increases and then decreases quickly. Class 2 is 
represented by low and steady cytokine values. Class 3 is represented by moderate initial cytokine 
values with slow decline. Class 4 is represented by higher initial cytokine values that decline 
slowly at first then quicker as time progresses. In this model 0.18 % of the patients belong to Class 
1, 45.9% of the patients belong to Class 2, 47.54% of the patients belong to Class 3 and 6.38% of 
the patients belong to Class 4. A majority of the patient belong to Class 3. Mortality is as follows: 
Class 1 0%, Class 2 23.81%, Class 3 20.69% and Class 4 31.43%. A figuring showing the 
trajectory classes is shown below. 
 The overall analysis of IL10 using ln (hours+1) times in the complete measurement cohort 
is considered Model 4. Parameter estimates for Model 4 can be found in the table below. Class 1 
is represented by the highest cytokine value with slow decline. Class 2 is represented by low and 
steady cytokine values. Class 3 is represented by high initial cytokine values that decline quickly. 
In this model 6.01% of the patients belong to Class 1, 69.03% of the patients belong to Class 2 and 
24.95% of the patients belong to Class 3. A majority of the patients belong to Class 2. Mortality is 
as follows: Class 1 51.61%, Class 2 25.07%, and Class 3 19.67%. A figuring showing the trajectory 
classes is shown below. 
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Figure 5. Overall Analysis of IL6 in Complete Measurement Cohort Using Ln (hours+1) Times – 
Model 3 
 
Figure 6. Overall Analysis of IL10 in Complete Measurement Cohort Using Ln (hours+1) Times – 
Models 4 
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Table 4. Parameter Estimates for Model 3 
 COEFFICIENT STANDARD 
ERROR 
WALD TEST 
STATISTIC 
P-
VALUE 
CLASS 1 INTERCEPT (NOT ESTIMATED) 0 - - - 
CLASS 2 INTERCEPT 4.93858 1.88285 2.623 0.00872 
CLASS 3 INTERCEPT 8.21856 1.89139 4.345 0.00001 
CLASS 4 INTERCEPT 12.72625 2.00175 6.358 <0.0001 
TIME CLASS 1 9.64188 1.1511 8.376 <0.0001 
TIME CLASS 2 -0.02286 0.08747 -0.261 0.79385 
TIME CLASS 3 0.23732 0.09473 2.505 0.01224 
TIME CLASS 4 0.06125 0.26127 0.234 0.81464 
TIME SQUARED CLASS 1 -2.19693 0.25501 -8.615 <0.0001 
TIME SQUARED CLASS 2 -0.03079 0.02455 -1.254 0.20968 
TIME SQUARED CLASS 3 -0.3066 0.02904 -10.557 <0.0001 
TIME SQUARED CLASS 4 -0.536 0.0705 -7.602 <0.0001 
 
 
 
 
 
  
Table 5. Parameter Estimates for Model 4 
 COEFFICIENT STANDARD 
ERROR 
WALD TEST 
STATISTIC 
P-
VALUE 
CLASS 1 INTERCEPT (NOT ESTIMATED) 0 - - - 
CLASS 2 INTERCEPT -4.56272 0.36312 -12.565 <0.0001 
CLASS 3 INTERCEPT -0.675 0.40579 -1.663 0.09623 
TIME CLASS 1 0.53142 0.2322 2.289 0.0221 
TIME CLASS 2 0.08182 0.06711 1.219 0.22278 
TIME CLASS 3 -0.28908 0.12668 -2.282 0.02249 
TIME SQUARED CLASS 1 -0.28447 0.06253 -4.549 0.00001 
TIME SQUARED CLASS 2 -0.08569 0.01771 -4.839 <0.0001 
TIME SQUARED CLASS 3 -0.27181 0.03244 -8.378 <0.0001 
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3.6 INCREASING/DECREASING ANALYSIS IN WHOLE COHORT 
The increasing analysis of IL6 in the whole cohort using ln (hours+1) times is considered Model 
5. Parameter estimates for Model 5 can be found in the table below. Class 1 is represented by a 
higher initial cytokine value with slow increase and then decrease. Class 2 is represented by lower 
initial cytokine value and even smaller increase and decrease than Class 1. The figure below shows 
this 2 class trajectory model. In this model 52.48% of the patients belong to Class 1 and 47.52% 
of the patients belong to Class 2. A majority of the patients belong to Class 1. Mortality is as 
follows: Class 1 37.36% and Class 2 34.78%. 
 The increasing analysis of IL10 in the whole cohort using ln (hours+1) times is considered 
Model 6. Parameter estimates for Model 6 can be found in the table below. Class 1 is represented 
by lower initial cytokine value with a small increase and then decrease. Class 2 is represented by 
a higher initial cytokine value with a larger increase and decrease than Class 1. The figure below 
shows this 2 class trajectory model. In this model 61.64% of the patients belong to Class 1 and 
38.36% of the patients belong to Class 2. A majority of the patients belong to Class 1. Mortality is 
as follows: Class 1 34.07% and Class 2 42.31%. 
 The decreasing analysis of IL6 in the whole cohort using ln (hours+1) times is considered 
Model 7. Parameter estimates for Model 7 can be found in the table below. Class 1 is represented 
by moderate initial values and moderate decline. Class 2 is represented by low initial value that 
almost remains steady. Class 3 is represented by high initial value and slow decline followed by 
more rapid decline. The figure below shows this 3 class trajectory model. In this model 37.53% of 
the patients belong to Class 1, 56.17% of the patients belong to Class 2 and 6.3% of the patients 
belong to Class 3. A majority of the patients belong to Class 2. Mortality is as follows: Class 1 
22.66%, Class 2 24.74% and Class 3 59.09%. 
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 The decreasing analysis of IL10 in the whole cohort using ln (hours+1) times is considered 
Model 8. Parameter estimates for Model 8 can be found in the table below. Class 1 is represented 
by low and steady cytokine values. Class 2 is represented by higher initial values that decline 
slowly. The figure below shows this 2 class trajectory model. In this model 78.06% of the patients 
belong to Class 1 and 21.94% of the patients belong to Class 2. A majority of the patients belong 
to Class 1. Mortality is as follows: Class 1 27.71% and Class 2 31.25%. 
 When considering Il6, the overall mortality in the increasing group was 36.07% and the 
overall mortality in the decreasing group was 26.16%. The proportion of patients dying at 60 days 
from any cause in the increasing group is significantly different than the decreasing group with a 
p-value of 0.0177. When considering Il10, the overall mortality in the increasing group was 
37.06% and the overall mortality in the decreasing group was 28.47%. The proportion of patients 
dying at 60 days from any cause in the increasing group was not significantly different from the 
decreasing group with a p-value of 0.0691. 
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Figure 7. Increasing Analysis of IL6 in Whole Cohort Using Ln (hours+1) Times – Model 5 
 
 
Figure 8. Increasing Analysis of IL10 in Whole Cohort Using Ln (hours+1) Times – Model 6 
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Figure 9. Decreasing Analysis of IL6 in Whole Cohort Using Ln (hours+1) Times – Model 7 
 
 
 
Figure 10. Decreasing Analysis of IL10 in Whole Cohort Using Ln (hours+1) Times – Model 8 
 
 29 
Table 6. Parameter Estimates for Model 5 
 COEFFICIENT STANDARD 
ERROR 
WALD TEST 
STATISTIC 
P-
VALUE 
CLASS 1 INTERCEPT (NOT ESTIMATED) 0 - - - 
CLASS 2 INTERCEPT -2.57337 0.58335 -4.411 0.00001 
TIME CLASS 1 1.22398 0.17978 6.808 <0.0001 
TIME CLASS 2 0.90315 0.14756 6.12 <0.0001 
TIME SQUARED CLASS 1 -0.44379 0.06055 -7.329 <0.0001 
TIME SQUARED CLASS 2 -0.212 0.04358 -4.865 <0.0001 
 
 
Table 7. Parameter Estimates for Model 6 
 COEFFICIENT STANDARD 
ERROR 
WALD TEST 
STATISTIC 
P-
VALUE 
CLASS 1 INTERCEPT (NOT ESTIMATED) 0 - - - 
CLASS 2 INTERCEPT 2.86655 0.39863 7.191 <0.0001 
TIME CLASS 1 0.8766 0.14221 6.164 <0.0001 
TIME CLASS 2 1.4567 0.19131 7.614 <0.0001 
TIME SQUARED CLASS 1 -0.25425 0.03787 -6.714 <0.0001 
TIME SQUARED CLASS 2 -0.58388 0.06024 -9.693 <0.0001 
 
 
Table 8. Parameter Estimates for Model 7 
 COEFFICIENT STANDARD 
ERROR 
WALD TEST 
STATISTIC 
P-
VALUE 
CLASS 1 INTERCEPT (NOT ESTIMATED) 0 - - - 
CLASS 2 INTERCEPT -4.03315 0.35505 -11.359 <0.0001 
CLASS 3 INTERCEPT 5.16057 0.96934 5.324 <0.0001 
TIME CLASS 1 -0.21468 0.14974 -1.434 0.15166 
TIME CLASS 2 -0.71197 0.10185 -6.99 <0.0001 
TIME CLASS 3 0.36568 0.3564 1.026 0.30488 
TIME SQUARED CLASS 1 -0.33486 0.05155 -6.496 <0.0001 
TIME SQUARED CLASS 2 0.05366 0.03041 1.765 0.07758 
TIME SQUARED CLASS 3 -0.69001 0.10522 -6.558 <0.0001 
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Table 9. Parameter Estimates for Model 8 
 COEFFICIENT STANDARD 
ERROR 
WALD TEST 
STATISTIC 
P-
VALUE 
CLASS 1 INTERCEPT (NOT ESTIMATED) 0 - - - 
CLASS 2 INTERCEPT -3.90296 0.92644 -4.213 0.00003 
TIME CLASS 1 -0.37277 0.26982 -1.382 0.16711 
TIME CLASS 2 -0.74246 0.09728 -7.632 <0.0001 
TIME SQUARED CLASS 1 -0.31945 0.10733 -2.976 0.00292 
TIME SQUARED CLASS 2 0.03455 0.02751 1.256 0.20925 
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3.7 INCREASING/DECREASING ANALYSIS IN COMPLETE MEASUREMENT 
COHORT 
The increasing analysis of IL6 in the complete measurement cohort using ln (hours+1) times is 
considered Model 9. Parameter estimates for Model 9 can be found in the table below. Class 1 is 
represented by lower initial cytokine value with a small increase and then decrease. Class 2 is 
represented by a higher initial cytokine value with a larger increase and decrease than Class 1. The 
figure below shows this 2 class trajectory model. In this model 47.34% of the patients belong to 
Class 1 and 52.66% of the patients belong to Class 2. A majority of the patients belong to Class 2. 
Mortality is as follows: Class 1 35.53% and Class 2 33.33%. 
 The increasing analysis of IL10 in the complete measurement cohort using ln (hours+1) 
times is considered Model 10. Parameter estimates for Model 10 can be found in the table below. 
Class 1 is represented by lower initial cytokine values with a small increase and then decrease. 
Class 2 is represented by a higher initial cytokine value with a larger increase and decrease than 
Class 1. The figure below shows this 2 class trajectory model. In this model 63.49% of the patients 
belong to Class 1 and 36.51% of the patients belong to Class 2. The majority of patients belong to 
Class 1. Mortality is as follows: Class 1 32.88% and Class 2 35.00%. 
 The decreasing analysis of IL6 in the complete measurement cohort using ln (hours+1) 
times is considered Model 11. Parameter estimates for Model 11 can be found in the table below. 
Class 1 is represented by moderate initial values and moderate decline. Class 2 is represented by a 
low initial value that remains steady. Class 3 is represented by high initial value and slow decline 
followed by more rapid decline. The figure below shows this 3 class trajectory model. In this model 
42.39% of the patients belong to Class 1, 51.04% of the patients belong to Class 2 and 6.57% of 
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the patients belong to class 3. A majority of the patients belong to Class 2.  Mortality is as follows: 
Class 1 18.4%, Class 2 22.15% and Class 3 45.00%. 
 The decreasing analysis of IL10 in the complete measurement cohort with ln (hours+1) 
times is considered Model 12. Parameter estimates for Model 12 can be found in the table below. 
Class 1 is represented by low and steady cytokine values. Class 2 is represented by higher initial 
cytokine values that decline slowly.  The figure below shows this 2 class trajectory model. In this 
model 71.58% of the patients belong to Class 1 and 28.42% of the patients belong to Class 2. A 
majority of the patients belong to Class 1. Mortality is as follows: Class 1 26.09% and Class 2 
23.61%. 
 When considering Il6, the overall mortality in the increasing group was 34.44% and the 
overall mortality in the decreasing group was 22.11%. The proportion of patients dying at 60 days 
from any cause in the increasing group is significantly different from the decreasing group with a 
p-value of 0.0049. When considering Il10, the overall mortality in the increasing group was 
33.63% and the overall mortality in the decreasing group was 25.39%. The proportion of patients 
dying at 60 days from any cause in the increasing group was not significantly different from the 
decreasing group with a p-value of 0.1040. 
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Figure 11. Increasing Analysis of IL6 in Complete Measurement Cohort Using Ln (hours+1) Times – 
Model 9 
 
 
 
 
Figure 12. Increasing Analysis of IL10 in Complete Measurement Cohort Using Ln (hours+1) Times 
– Model 10 
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Figure 13. Decreasing Analysis of IL6 in Complete Measurement Cohort Using Ln (hours+1) Times – 
Model 11 
 
 
Figure 14. Decreasing Analysis of IL10 in Complete Measurement Cohort Using Ln (hours+1) Times 
– Model 12 
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Table 10. Parameter Estimates for Model 9 
 COEFFICIENT STANDARD 
ERROR 
WALD TEST 
STATISTIC 
P-
VALUE 
CLASS 1 INTERCEPT (NOT ESTIMATED) 0 - - - 
CLASS 2 INTERCEPT 2.29886 0.66318 3.466 0.00053 
TIME CLASS 1 0.92019 0.17021 5.406 <0.0001 
TIME CLASS 2 1.1843 0.1884 6.286 <0.0001 
TIME SQUARED CLASS 1 -0.21823 0.05155 -4.234 0.00002 
TIME SQUARED CLASS 2 -0.42738 0.06196 -6.898 <0.0001 
 
 
Table 11. Parameter Estimates for Model 10 
 COEFFICIENT STANDARD 
ERROR 
WALD TEST 
STATISTIC 
P-
VALUE 
CLASS 1 INTERCEPT (NOT ESTIMATED) 0 - - - 
CLASS 2 INTERCEPT 2.60822 0.42978 6.069 <0.0001 
TIME CLASS 1 0.92006 0.155 5.936 <0.0001 
TIME CLASS 2 1.39951 0.20624 6.786 <0.0001 
TIME SQUARED CLASS 1 -0.2688 0.0429 -6.265 <0.0001 
TIME SQUARED CLASS 2 -0.55909 0.06358 -8.794 <0.0001 
 
 
Table 12. Parameter Estimates for Model 11 
 COEFFICIENT STANDARD 
ERROR 
WALD TEST 
STATISTIC 
P-
VALUE 
CLASS 1 INTERCEPT (NOT ESTIMATED) 0 - - - 
CLASS 2 INTERCEPT -3.77528 0.35546 -10.621 <0.0001 
CLASS 3 INTERCEPT 5.29336 0.82155 6.443 <0.0001 
TIME CLASS 1 -0.25107 0.13387 -1.875 0.06073 
TIME CLASS 2 -0.72525 0.11031 -6.574 <0.0001 
TIME CLASS 3 0.01981 0.37843 0.052 0.95824 
TIME SQUARED CLASS 1 -0.31137 0.04566 -6.819 <0.0001 
TIME SQUARED CLASS 2 0.06368 0.03347 1.902 0.05714 
TIME SQUARED CLASS 3 -0.63789 0.10127 -6.299 <0.0001 
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Table 13. Parameter Estimates for Model 12 
 COEFFICIENT STANDARD 
ERROR 
WALD TEST 
STATISTIC 
P-
VALUE 
CLASS 1 INTERCEPT (NOT ESTIMATED) 0 - - - 
CLASS 2 INTERCEPT 3.2259 0.37979 8.494 <0.0001 
TIME CLASS 1 -0.73392 0.09918 -7.4 <0.0001 
TIME CLASS 2 -0.52825 0.16825 -3.14 0.00169 
TIME SQUARED CLASS 1 0.04667 0.02519 1.853 0.06387 
TIME SQUARED CLASS 2 -0.25346 0.04786 -5.295 <0.0001 
 
3.8 MORTALITY PATTERNS 
The table below shows the 60 day all-cause mortality in each IL6/IL10 category. This table uses 
the results of the overall trajectory analyses in the whole cohort using ln (hours+1) times. Classes 
are ordered from low baseline cytokine value to high baseline cytokine value according to the 
appropriate trajectory analysis. As seen below, the highest mortality is seen in patients placed in 
IL6 class 2 and IL10 class 1.  
After running the chi-square tests, it was determined that the mortality rates for Class 2 
differ statistically from the mortality rates in Class 3, Class 1 and Class 4 when considering IL6. 
Mortality rates for Class 1 differ from Class 3 and Class 2 when considering IL10.  
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Table 14. IL6/IL10 Mortality Comparison* 
 IL6 Class 3 IL6 Class 1 IL6 Class 4 IL6 Class 2 Total 
IL10 Class 3 260 (28.39%) 155 (25.19%) 2 (0.00%) 1 (0.00%) 418 (27.01%) 
IL10 Class 2 39 (17.65%) 76 (25.35%) 13 (11.11%) 0 (NA) 128 (21.93%) 
IL10 Class 1 12 (36.36%) 37 (42.86%) 2 (50.00%) 7 (100.00%) 58 (48.15%) 
IL10 Class 4 1 (0.00%) 14 (38.46%) 15 (38.46%) 4 (75.00%) 34 (41.94%) 
Total 312 (27.30%) 282 (28.35%) 32 (26.92%) 12 (81.82%) 638 (28.80%) 
* Values in the table are Total N (Mortality Rate) 
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4.0  DISCUSSION 
In this study, both the whole and complete measurement cohorts looked similar clinically although 
the high mortality in the incomplete measurement group drove up the mortality in the whole cohort 
making it statistically different from the mortality rate in the complete measurement cohort. It is 
also important to note that many individuals in the incomplete measurement group die before 3 
days. Not only are the individuals in this group sicker, but they are also dying earlier than in the 
other two cohorts.  
 In regards to modeling, the decreasing analysis of IL6 in all subgroups was modeled with 
three groups. The reason for this additional group is based on the clinical understanding that IL6 
would have a flat group, a slowly decreasing group and a rapidly decreasing group. The resulting 
models confirmed these beliefs.  
In the overall analysis of the whole cohort for Il6, the highest mortality is in the highest 
initial value class. In the overall analysis of the complete measurement cohort for Il6, the highest 
mortality is also in the highest initial value class. The shape of the resulting classes from the whole 
and complete measurement cohorts are very similar with the addition of the rising class in the 
complete measurement cohort. It is important to note the extremely small number of individuals 
being placed into this increasing class.  
In the overall analysis of the whole cohort for IL10, Class 1 has a higher mortality rate then 
Class 4 even though Class 4 has a higher initial IL10 value. This suggests that the higher mortality 
in Class 1 is driven by the high initial value as well as the slower decline over time. This idea is 
reinforced once again in the overall analysis of the complete measurement cohort. Even though 
Class 1 and Class 3 have similar initial values, the higher mortality is in the class that declines 
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slower. The trajectory classes for IL10 in both the whole and complete measurement cohorts are 
extremely similar in shape and interpretation.  
In the increasing/decreasing analysis, the highest mortality was in the group with the 
highest initial cytokine value with two exceptions. These exceptions are both in the complete 
measurement cohort and are seen in the Il6 increasing model and Il10 decreasing model. In both 
of these models the lower of the two curves has the lower mortality. Even though it is lower, the 
mortality levels in the two groups are very similar. Models of increasing/decreasing subsets look 
very similar between cohorts.  
When looking at IL6 in both cohorts, there is a statistically significant difference in 
mortality between those who increase from 0 to 6 and those who decrease from 0 to 6. It was 
originally suspected that those who initially rise were caught earlier and would have better 
outcomes but this is not the case. Instead, those who rise initially have higher mortality. This 
indicates that these individuals are sicker. Although it was not significant in IL10, the same trend 
is present.  
When comparing classes of IL6 and IL10 simultaneously, we see the same trend presented 
in the univariate interpretations. In all combinations of IL10 with IL6 Class 4, a higher initial level 
of IL6 does not indicate highest mortality. Mortality is much lower in Il6 Class 4 than Class 2 
because of the quicker drop. We see the highest mortality not in the highest IL6/IL10 class but in 
the highest IL6 class crossed with the third highest IL10 class but this is not strong support given 
the small number of individuals in this category.  
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All in all, the analyses presented support the following key findings: 
• Mortality in IL6 and IL10 is not only based on initial values 
• Rate of decent plays a key role in mortality  
• Increasing cytokine values from time 0 to time 6 indicate worse outcomes 
• Interpretation from both cohorts presents similar findings 
 
These results further qualify the results of Kellum et al who state that the highest mortality 
can be found in those with high/high combinations of IL6 and IL10. The difference in our results 
can be attributed to the completeness of the ProCESS data set and the addition of increasing 
trajectories. As shown in this study and the study by Kellum et al, there is information in 
longitudinal data. 
In regards to bias, it is clear that using either of the cohorts would have produced similar 
results therefore the survivor bias is not apparent in the complete measurement cohort. 
4.1 LIMITATIONS 
One of the main limitations of this study lies the determination of classes. Although BIC is an 
excellent method for choosing the number of classes, it also has its flaws. Using BIC alone can 
produce classes with as little as 1 or 2 individuals. Looking at the mortality rates in these small 
classes can be deceiving. Therefore, it is up to the clinician and the statistician to determine the 
optimal number of classes based on the BIC, while also considering class size and clinical 
significance.   
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The data itself is limited in regards to defining time 0. In this study, time 0 is the entrance 
into the study. Unfortunately, study entrance does not coordinate exactly with onset of disease. 
Therefore, individuals could have seen a peak in their IL6 or IL10 before arriving at the emergency 
department.  
Another limitation lies in the LCMM program itself. When constructing models, LCMM 
will produce trajectories of a given polynomial form even if some of the terms are not significant 
in one of the classes. Although this is not a major concern, it is not optimal. Also, when 
constructing models, LCMM only allows time to be modeled in polynomial form. Other 
distribution forms of time may be of interest but are unable to be investigated at this time. Lastly, 
it is important to note that there is no biological explanation for the spline transform and it was 
only used to better fit data. 
4.2 FUTURE DIRECTION 
In the future, it would be of value to find a program that produced multivariate trajectory models 
in a useful way. Although LCMM does have a multlcmm option that does multivariable analysis, 
this method was unable to derive mixed classes of high IL6/low IL10. As mentioned previously, 
time 0 in this study is not reflective of the true start of disease progression, it instead reflects 
entrance into the study. It would therefore be useful to be able to determine the offset from true 
time zero for each patient and shift them accordingly. For example, if an individual developed 
sepsis 6 hours before being admitted into the study, their 0, 6, 24 and 72 hour time points should 
be shifted to 6, 12, 30 and 78. 
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4.3 PUBLIC HEALTH SIGNIFICANCE 
Given the public health significance of sepsis, understanding the prognosis is extremely important. 
Previously, having a high IL6 measurement implied a poor prognosis. Our results show that many 
factors play into the determination of prognosis and patients can be treated accordingly.  
 43 
BIBLIOGRAPHY 
Angus, D. C., Linde-Zwirble, W. T., Lidicker, J., Clermont, G., Carcillo, J., & Pinsky, M. R. 
(2001). Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, 
and associated costs of care. Critical Care Medicine, 29(7), 1303–1310. 
http://doi.org/10.1097/00003246-200107000-00002 
Commenges, D., & Jacqmin-Gadda, H. (2016). Dynamical Biostatistical Models. Boca Raton: 
CRC Press.  
Hotchkiss, R. S., & Karl, I. E. (2003). The pathophysiology and treatment of sepsis. The New 
England Journal of Medicine, 348(2), 138–50. http://doi.org/10.1056/NEJMra021333 
Kellum, J. A. (2008). Understanding the Inflammatory Cytokine Response in Pneumonia and 
Sepsis. The Journal of Emergency Medicine, 34(1), 112. 
http://doi.org/10.1016/j.jemermed.2007.10.008 
Process Investigators. (2014). A Randomized Trial of Protocol-Based Care for Early Septic Shock. 
Process trial. The New England Journal of Medicine, 370(18), 1–11. 
http://doi.org/10.1056/NEJMoa1401602 
Proust-Lima, C., Philipps, V., & Liquet, B. (n.d.). Estimation of Extended Mixed Models Using 
Latent Classes and Latent Processes: The R Package lcmm. 
Ramsay, J. O. (1988). Monotone Regression Splines in Action. Statistical Science, 3(4), 425–441. 
http://doi.org/10.1214/ss/1177012761 
 
